Nurix Therapeutics Welcomes Esteemed Biopharmaceutical Executive Roger Dansey, M.D., to Its Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy NRIX?
Source: Newsfilter
Appointment of Dr. Roger Dansey: Nurix Therapeutics has appointed Dr. Roger Dansey, a seasoned expert in oncology with extensive leadership experience, to its board of directors to enhance its strategic direction in drug development.
Focus on Targeted Protein Degradation: Nurix is pioneering targeted protein degradation medicines aimed at treating cancer and autoimmune diseases, with a clinical pipeline that includes innovative therapies like bexobrutideg for chronic lymphocytic leukemia.
Dr. Dansey's Background: Dr. Dansey has held significant roles in major pharmaceutical companies, including Pfizer and Seagen, and has contributed to the development of several breakthrough cancer therapies, bringing valuable expertise to Nurix.
Company's Vision and Pipeline: Nurix aims to revolutionize drug discovery with its AI-integrated platform and has a robust pipeline of clinical and preclinical candidates, including collaborations with major pharmaceutical companies for co-development and commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRIX
Wall Street analysts forecast NRIX stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.810
Low
22.00
Averages
31.08
High
41.00
Current: 15.810
Low
22.00
Averages
31.08
High
41.00
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Redmile Group Acquires Additional Shares of Nurix Therapeutics
- Share Acquisition: On February 17, 2026, Redmile Group disclosed the purchase of 4,415,514 shares of Nurix Therapeutics, valued at approximately $63.43 million based on the average price from Q4 2025, indicating sustained confidence in the company.
- Increased Ownership: Following this acquisition, Redmile's stake in Nurix now represents 11.31% of its $1.358 billion in 13F reportable AUM, highlighting its significant commitment to the biopharmaceutical sector.
- Financial Overview: As of February 17, 2026, Nurix's stock price stood at $15.64, down 6.52% year-over-year and trailing the S&P 500 by 23 percentage points, reflecting market caution regarding its future growth prospects.
- R&D Progress and Challenges: Nurix ended fiscal 2025 with $592.9 million in cash and marketable securities, while generating $84 million in revenue, yet incurring $316.9 million in R&D expenses, indicating a capital-intensive strategy amidst accelerated clinical program development.
See More
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares
- Share Acquisition: On February 17, 2026, Redmile Group acquired an additional 4,415,514 shares of Nurix Therapeutics, with an estimated trade value of $63.43 million, reflecting its ongoing confidence in the biotechnology sector.
- Increased Position Value: By quarter-end, Redmile's total position in Nurix reached $153.54 million, an increase of $119.55 million from the previous quarter, indicating that the company's strategic positioning in the biopharmaceutical market is yielding positive results.
- R&D Investment: Nurix's R&D spending for fiscal 2025 hit $316.9 million, and despite a widened net loss of $264.5 million, the accelerated clinical program development underscores the company's strong belief in future growth prospects.
- Market Competitiveness: Although Nurix's stock has declined over the past year, the advancement of its BTK degrader, bexobrutideg, into a registrational DAYBreak program highlights the company's innovative potential in oncology and immune disorders, which may yield returns for long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Redmile Group Acquires Additional Shares of Nurix Therapeutics
- Share Acquisition: On February 17, 2026, Redmile Group disclosed the purchase of 4,415,514 shares of Nurix Therapeutics, valued at approximately $63.43 million based on the average price from Q4 2025, indicating sustained confidence in the company.
- Increased Ownership: Following this acquisition, Redmile's stake in Nurix now represents 11.31% of its $1.358 billion in 13F reportable AUM, highlighting its significant commitment to the biopharmaceutical sector.
- Financial Overview: As of February 17, 2026, Nurix's stock price stood at $15.64, down 6.52% year-over-year and trailing the S&P 500 by 23 percentage points, reflecting market caution regarding its future growth prospects.
- R&D Progress and Challenges: Nurix ended fiscal 2025 with $592.9 million in cash and marketable securities, while generating $84 million in revenue, yet incurring $316.9 million in R&D expenses, indicating a capital-intensive strategy amidst accelerated clinical program development.
See More
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares
- Share Acquisition: On February 17, 2026, Redmile Group acquired an additional 4,415,514 shares of Nurix Therapeutics, with an estimated trade value of $63.43 million, reflecting its ongoing confidence in the biotechnology sector.
- Increased Position Value: By quarter-end, Redmile's total position in Nurix reached $153.54 million, an increase of $119.55 million from the previous quarter, indicating that the company's strategic positioning in the biopharmaceutical market is yielding positive results.
- R&D Investment: Nurix's R&D spending for fiscal 2025 hit $316.9 million, and despite a widened net loss of $264.5 million, the accelerated clinical program development underscores the company's strong belief in future growth prospects.
- Market Competitiveness: Although Nurix's stock has declined over the past year, the advancement of its BTK degrader, bexobrutideg, into a registrational DAYBreak program highlights the company's innovative potential in oncology and immune disorders, which may yield returns for long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Wall Street Analysts Adjust META Stock Outlook
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on META stock, reflecting varying market perspectives on the company's future performance, which could influence investor decisions.
- Increased Market Attention: As analysts focus more on META, investors may reassess their portfolios, particularly against the backdrop of volatility in tech stocks.
- Rating Page Update: Comprehensive information on analyst rating changes can be found on our analyst ratings page, offering a complete view of META and other stocks to aid investors in making informed decisions.
- Lack of Investment Advice: While rating changes are provided, Benzinga does not offer specific investment advice, leaving investors to evaluate risks and rewards independently.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
